USB-PS — US BANCORP \DE\

NYSE · Financials · Banks · CIK 36104 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 7,260,000,000 1,945,000,000 700,998,000,000 48,420,000,000 634,751,000,000
Dec 2025 7,337,000,000 2,045,000,000 692,345,000,000 46,890,000,000 626,694,000,000
Sep 2025 7,300,000,000 2,001,000,000 695,357,000,000 66,637,000,000 631,559,000,000
Jun 2025 6,975,000,000 1,815,000,000 686,370,000,000 57,807,000,000 624,474,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$9,618,000,000
Investing CF
$-23,341,000,000
Financing CF
$11,819,000,000
CapEx
Dividends Paid
$-3,527,000,000
Buybacks
$-605,000,000
EPS Diluted TTM
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$81,944,000,000
Inventory
Receivables
$8,094,000,000
ST Investments
$93,456,000,000
EBIT TTM
Pretax Income TTM
$9,777,000,000
Interest Exp TTM
$14,472,000,000
Analysts

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 28,540,000,000 7,570,000,000 692,345,000,000 626,694,000,000 7,970,000,000
Dec 2024 27,335,000,000 6,299,000,000 678,318,000,000 619,278,000,000 11,350,000,000
Dec 2023 28,013,000,000 5,429,000,000 663,491,000,000 607,720,000,000 8,393,000,000
Dec 2022 24,184,000,000 5,825,000,000 674,805,000,000 623,573,000,000 21,119,000,000

TTM Snapshot

Revenues TTM
$31,680,000,000
NetIncome TTM
$6,474,000,000
OpCashFlow TTM
$0
Assets (Latest)
$678,318,000,000
Forward EPS

Peers — same industry

TickerNameMarket CapLastDaily %
WFC-PL WELLS FARGO & COMPANY/MN $5.53T $1174.99
USB-PA US BANCORP \DE\ $1.28T $761.17
JPM JPMORGAN CHASE & CO $901.58B $336.47
BAC BANK OF AMERICA CORP /DE/ $423.45B $59.67
RY ROYAL BANK OF CANADA $293.34B $211.09

News headlines (Yahoo Finance, 1h cache)

Here's Why U.S. Bancorp (USB) is a Great Momentum Stock to Buy
2026-07-10 16:00 · Yahoo
Stock Market Leadership Comes Into Focus With IBD Breakout Stocks Index
2026-07-10 14:23 · Yahoo
Fifth Third Bancorp (FITB) Reports Next Week: Wall Street Expects Earnings Growth
2026-07-10 14:00 · Yahoo
USB or BNY: Which Is the Better Value Stock Right Now?
2026-07-09 15:40 · Yahoo
U.S. Bancorp (USB) Earnings Expected to Grow: Should You Buy?
2026-07-09 14:00 · Yahoo
USB vs. BNY: Which Stock Is the Better Value Option?
2026-07-08 15:40 · Yahoo
U.S. Bank Launches Enhanced Payments to Help Small Businesses Move Money Quickly and More Affordably
2026-07-08 11:00 · Yahoo
U.S. Bancorp (USB) Price Target Lowered at Oppenheimer. Here is Why
2026-07-08 05:09 · Yahoo
Okta upgraded, Datadog downgraded: Wall Street's top analyst calls
2026-07-06 13:47 · Yahoo
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More
2026-07-06 11:52 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.